Hormonal
Relative hyperglucagonemia (inappropriate glucagon secretion relative to hyperglycemia) contributes to both fasting and postprandial hyperglycemia in Type 2 Diabetes by driving excessive hepatic glucose production.
In Type 2 Diabetes, high blood sugar isn't just about not having enough insulin; it's also about having too much glucagon, a hormone that tells your liver to release stored sugar. Newer medications (like GLP-1 agonists and DPP-4 inhibitors) work partly by fixing this glucagon imbalance, lowering blood sugar by stopping the liver from overproducing glucose.
Our overall conclusions are that there is considerable evidence that relative hyperglucagonemia contributes to fasting and postprandial hyperglycemia in patients with T2DM
Why this rating
The paper is a comprehensive review citing numerous human and animal studies, though it acknowledges some controversy.
Source
The Role of α-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
Beth E. Dunning et al. · Endocrine Reviews · 2007
DOI 10.1210/er.2006-0026
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →